Functional Vision With ACRYSOF® IQ IOLs Blue Light Filtration
Functional Benefit With ACRYSOF® Natural Chromophore
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pseudophakes with ACRYSOF® IQ monofocal IOLs or clear (no blue light filter) IOLs in both eyes for at least 3 months.
- Willing and able to understand and sign an informed consent form.
- Corrected visual acuity (CVA) of 20/40 or better.
- Have a valid driver's license.
- Depth perception of at least 100 arc seconds.
- Other protocol-specified inclusion criteria may apply.
Exclusion Criteria:
- Ocular pathology, degeneration, or media opacity.
- Color vision defect.
- Use of ocular or systemic medications that impact macular pigment density or reaction time, including but not limited to, lutein, zeaxanthin, barbiturates, tranquilizers or amphetamines.
- System conditions affecting connective tissue or sensory-motor coordination.
- Other protocol-specified exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: ACRYSOF IQ IOL
ACRYSOF® IQ IOL with or without clear clip-on glasses worn for 3 hours
|
Clip-on glasses with no blue light filtering properties used as a placebo
AcrySof IQ Aspheric Natural IOL Model SN60WF with UV and blue light filtering properties, previously implanted
|
|
Active Comparator: Clear IOL
Clear IOL with or without blue light filter clip-on glasses and clear clip-on glasses, worn in a cross-over fashion, as randomized, for 4 hours total
|
Clip-on glasses with no blue light filtering properties used as a placebo
Clip-on glasses with blue light filtering properties similar to ACRYSOF® IOLs
Clear IOL, previously implanted
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Braking Reaction Time From No-glare to Glare
Time Frame: Visit 2, up to Day 30
|
Braking reaction time (time to brake, in seconds) was assessed using a driving simulator in no-glare and glare conditions.
The subject was presented with a driving scenario during which an obstruction (car pulling over from either side of the road in a random fashion) was presented.
Subjects braked in an attempt to avoid colliding with the obstruction, and the braking reaction time was recorded.
The experiment was repeated with a glare source present.
Both assessments (no-glare and glare) occurred on the same day.
Change in braking reaction time was calculated as glare minus no-glare.
|
Visit 2, up to Day 30
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Braking Reaction Time From No-glare to Glare (Clear IOLs)
Time Frame: Visit 2, Up to Day 30
|
Braking reaction time (time to brake, in seconds) was assessed using a driving simulator in no-glare and glare conditions.
The subject was presented with a driving scenario during which an obstruction (car pulling over from either side of the road in a random fashion) was presented.
Subjects braked in an attempt to avoid colliding with the obstruction, and the braking reaction time was recorded.
The experiment was repeated with a glare source present.
Both assessments (no-glare and glare) occurred on the same day.
Change in braking reaction time was calculated as glare minus no-glare.
This outcome measure was pre-specified for Clear IOL only.
|
Visit 2, Up to Day 30
|
|
Change in Braking Reaction Time From No-glare to Glare (ACRYSOF® IQ IOL + Placebo Filter; Clear IOL + BLF)
Time Frame: Visit 2, Up to Day 30
|
Braking reaction time (time to brake, in seconds) was assessed using a driving simulator in no-glare and glare conditions.
The subject was presented with a driving scenario during which an obstruction (car pulling over from either side of the road in a random fashion) was presented.
Subjects braked in an attempt to avoid colliding with the obstruction, and the braking reaction time was recorded.
The experiment was repeated with a glare source present.
Both assessments (no-glare and glare) occurred on the same day.
Change in braking reaction time was calculated as glare minus no-glare.
|
Visit 2, Up to Day 30
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Sr Clinical Manager, GCRA-Global Med Affairs, Operations, Alcon Research
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Eye Diseases
- Lens Diseases
- Cataract
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Central Nervous System Stimulants
- Sympathomimetics
- Adrenergic Uptake Inhibitors
- Methamphetamine
- Adrenocorticotropic Hormone
- Melanocyte-Stimulating Hormones
- beta-Endorphin
Other Study ID Numbers
Other Study ID Numbers
- ILQ830-P001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.